CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Disease Team Research I |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
| Stanford University |
Dr. Alfred T Lane |
Disease Team Research I |
iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,039,208 |
| Stanford University |
Professor Irving L Weissman MD |
Disease Team Research I |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
| University of California, Los Angeles |
Dr. Dennis J Slamon |
Disease Team Research I |
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
| City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Disease Team Research I |
ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
| University of Southern California |
Mark Salman Humayun |
Disease Team Research I |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$18,904,916 |
| University of California, San Diego |
Dr. Dennis A Carson |
Disease Team Research I |
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
| University of California, San Diego |
Dr. Gene Wei-Ming Yeo |
Basic Biology I |
RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency |
$1,308,901 |
| University of California, San Diego |
Karl H. Willert |
Basic Biology I |
WNT signaling and the control of cell fate decisions in human pluripotent stem cells. |
$1,329,298 |
| University of California, Davis |
Dr. Min Zhao |
Basic Biology I |
Directing migration of human stem cells with electric fields |
$816,228 |
| University of California, Los Angeles |
Dr. Michael A. Teitell |
Basic Biology I |
Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
| University of Southern California |
Dr. Martin Pera |
Basic Biology I |
The stem cell microenvironment in the maintenance of pluripotency and reprogramming |
$1,325,723 |
| Stanford University |
Dr. Julien Sage |
Basic Biology I |
The retinoblastoma (RB) gene family in cellular reprogramming |
$1,357,085 |
| Stanford University |
Dr. Susan K McConnell |
Basic Biology I |
Identification and characterization of human ES-derived DA neuronal subtypes |
$1,404,853 |
| University of California, Los Angeles |
Bennett G Novitch |
Basic Biology I |
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,228,278 |
| University of California, Los Angeles |
Dr. Robb Maclellan Dr. |
Basic Biology I |
Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$917,667 |
| University of Southern California |
Dr. Wange Lu |
Basic Biology I |
Defining the molecular mechanisms of somatic cell reprogramming |
$1,365,580 |
| Stanford University |
Professor Helen M. Blau PhD |
Basic Biology I |
Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,408,332 |
| University of California, Los Angeles |
Dr. Luisa Iruela-Arispe |
Basic Biology I |
Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
| University of California, Irvine |
Dr. Aileen J Anderson |
Quest – Discovery Stage Research Projects |
Therapeutic targeting of Glioblastoma Stem Cell survival and self-renewal signaling |
$2,250,144 |
| Children’s Hospital of Los Angeles |
Dr Biraj Mahato |
Quest – Discovery Stage Research Projects |
Chemically engineered photoreceptors for vision restoration in retinal degeneration associated blindness. |
$1,711,000 |
| University of California, San Francisco |
Claire Clelland |
Quest – Discovery Stage Research Projects |
Developing a universal CRISPR gene therapy approach to treat C9orf72 ALS |
$2,740,592 |
| University of California, Los Angeles |
Dr. Koki Morizono |
Quest – Discovery Stage Research Projects |
B cell receptor-mediated lentiviral expression of anti-HIV antibody |
$2,751,504 |
| University of California, San Francisco |
Faranak Fattahi |
Quest – Discovery Stage Research Projects |
Drug discovery for Charcot Marie Tooth Disease using hPSC-derived Schwann cells |
$2,471,664 |
| City of Hope, Beckman Research Institute |
Dr. Christine E. Brown |
Quest – Discovery Stage Research Projects |
Development of a Trifunctional Self-Renewing Memory CAR T Cell Therapy to Overcome the Heterogeneity and Suppressive Microenvironment of Glioblastoma |
$2,700,810 |
| University of California, San Diego |
Dr. Neil Carson Chi |
Quest – Discovery Stage Research Projects |
Modulating cardiac myosin heavy chain isoform expression for treating cardiomyopathies |
$2,772,000 |
| University of California, San Francisco |
Dr. Qizhi Tang PhD |
Quest – Discovery Stage Research Projects |
Genome editing of human Tregs to enable combinational tolerogenic therapy with T cell-targeted biologics for T1D |
$2,485,549 |
| Palo Alto Veterans Institute for Research |
Dr. Jian Luo |
Quest – Discovery Stage Research Projects |
Human induced pluripotent stem cells-derived glial enriched progenitors for the treatment of mild traumatic brain injury |
$2,255,189 |
| Palo Alto Veterans Institute for Research |
Irene Lorenzo Llorente |
Quest – Discovery Stage Research Projects |
Inhibitory interneurons derived from human induced pluripotent stem cells to treat stroke |
$2,140,122 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Quest – Discovery Stage Research Projects |
Gene-corrected human microglia for the treatment of adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) |
$1,417,948 |
| University of California, San Francisco |
Faranak Fattahi |
Quest – Discovery Stage Research Projects |
Drug discovery for gastrointestinal motility disorders using hPSC-derived enteric ganglioids |
$1,954,367 |
| University of Southern California |
Dr. Justin K Ichida |
Quest – Discovery Stage Research Projects |
Development of a VAV2 antisense oligonucleotide (ASO) treatment for ALS |
$2,072,560 |
| Cedars-Sinai Medical Center |
Dr. Ritchie Ho |
Quest – Discovery Stage Research Projects |
C9orf72 repeat expansion-tuned allelic suppression by CRISPRi as an ALS therapy |
$2,274,768 |
| University of California, Davis |
Ricardo Anibal Maselli MD |
Quest – Discovery Stage Research Projects |
Treatment of Myasthenic Syndrome due to Choline Acetyltransferase Deficiency Using AAV9-mediated Gene Therapy |
$1,500,000 |
| Adverum Biotechnologies Inc. |
Cameron Keast Baker |
Quest – Discovery Stage Research Projects |
Development of an Optogenetic Vision Restoration Gene Therapy Using an Engineered Form of Melanopsin |
$1,150,820 |
| Stanford University |
Dr. Robert Negrin MD |
Quest – Discovery Stage Research Projects |
Orthogonal IL2 Receptor Transduced Regulatory T Cells for Clinical Application |
$1,920,652 |
| University of California, San Francisco |
Michael Wilson |
Quest – Discovery Stage Research Projects |
A First-in-Class Treatment for Progressive Multifocal Leukoencephalopathy Via Multimodal Immune System Engineering |
$2,182,396 |
| Stanford University |
Dr. Michael F Clarke |
Quest – Discovery Stage Research Projects |
Developing a breast cancer stem cell drug |
$2,053,727 |
| Cedars-Sinai Medical Center |
Dr. Ke Liao |
Quest – Discovery Stage Research Projects |
RNA-based therapeutics to augment regulatory T cells: a novel approach to treat myocarditis |
$2,264,509 |
| University of Southern California |
Dr Linda Sher M.D. |
Quest – Discovery Stage Research Projects |
Assessing the Functional, Immunologic and Microbiologic Characteristics of Human Livers Created in Chimeric Pigs |
$2,736,590 |
| University of California, Irvine |
Jianhua Yu |
Quest – Discovery Stage Research Projects |
Reprogramming Somatic Cells into iPSCs Engineered with an Anti-PSCA CAR to Develop Allogeneic Off-the-Shelf Cell Therapy to Treat Pancreatic Cancer |
$1,509,000 |
| City of Hope, Beckman Research Institute |
Dr Jianhua Yu |
Quest – Discovery Stage Research Projects |
Reprogramming Somatic Cells into iPSCs Engineered with an Anti-PSCA CAR to Develop Allogeneic Off-the-Shelf Cell Therapy to Treat Pancreatic Cancer |
$525,468 |
| Vertuis Bio, Inc. |
Lukas Bachmann |
Quest – Discovery Stage Research Projects |
Expanded Capacity AAV Retinal Gene Therapy Enabled by Efficient RNA-Joining Technology |
$0 |
| Gladstone Institutes, J. David |
Lyandisha Zholudeva |
Quest – Discovery Stage Research Projects |
Excitatory spinal interneurons from human pluripotent stem cells to treat spinal cord injury |
$2,942,198 |
| University of California, Los Angeles |
Prof. Song Li |
Quest – Discovery Stage Research Projects |
Vax-CT to promote formation of cancer-specific T memory stem cell for personalized cancer immunotherapy |
$2,267,714 |
| University of California, Los Angeles |
Dr. Richard Joseph Pietras |
Quest – Discovery Stage Research Projects |
Reversal of dysregulated myelopoiesis in breast cancers and cancer stem cells to boost antitumor immunotherapy |
$2,327,680 |
| Greenstone Biosciences, Inc. |
Paul D Pang |
Quest – Discovery Stage Research Projects |
Drug Discovery for Duchenne Muscular Dystrophy Using Patient-Derived Human iPSCs |
$675,000 |
| University of California, Berkeley |
Mr. Fyodor Urnov |
Quest – Discovery Stage Research Projects |
A Treatment for Artemis-deficient Severe Combined Immunodeficiency using Non-Viral CRISPR-driven Safe Harbor Transgenesis in Hematopoietic Stem Cells |
$1,809,372 |
| University of California, Davis |
Aijun Wang PhD |
Quest – Discovery Stage Research Projects |
In Utero Treatment of Duchenne Muscular Dystrophy with Non-viral Gene Editing |
$2,035,544 |
| Rubedo Life Sciences Inc. |
Marco Quarta |
Quest – Discovery Stage Research Projects |
Pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting the senescent niche of lung progenitor cells. |
$1,450,876 |